Skip to content

Investors

Calliditas leverages considerable experience in drug development and proprietary formulation expertise to selectively explore treatments for orphan diseases in which there is strong rationale and high unmet need. To that end, we seek to maximize the potential of our products by commercializing on a standalone basis in the United States market and through strategic partnerships in other regions. Additionally, we are interested in enhancing our product portfolio by identifying and in-licensing additional, late-stage product candidates that are a strong strategic and commercial fit.

INTERIM REPORT Q3 2022

On November 14, 2022, at 07:00 CEST, Calliditas Therapeutics published its interim report for the third quarter 2022.

IR Contact

Marie Galay

IR and Sustainability Manager
+44 7955129845